USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/2933
Full metadata record
DC FieldValueLanguage
dc.contributor.authorOrlandi-Jorquera, Cecilia
dc.contributor.authorMoran-Cardenas, María Gabriela
dc.contributor.authorEscobar-Huenchul, Valery Magdalena
dc.date.accessioned2019-06-24T22:33:02Z
dc.date.available2019-06-24T22:33:02Z
dc.date.issued2016
dc.identifier.citationORLANDI-JORQUERA, Cecilia, MORAN-CARDENAS, María Gabriela, ESCOBAR-HUENCHUL, Valery Magdalena. Comparative clinical study of depigmentation products on facial melasma in Latin women. In: Curierul Medical. 2016, vol. 59, no 4, pp. 29-32. ISSN 1875-0666.
dc.identifier.issn1857-0666
dc.identifier.urihttp://moldmedjournal.md/wp-content/uploads/2016/09/Cm-4-2016-PDF.pdf
dc.identifier.urihttp://repository.usmf.md/handle/20.500.12710/2933
dc.description.abstractBackground: Hyperpigmented lesions need the most frequent dermatological consultations, the acquired ones being more effectively treated. Out of them, the most common is melasma, which is currently treated with hydroquinone. Our objective was to compare the efficacy of a treatment based on Diacetylboldine-DAB, Alpha arbutin and Licorice with hydroquinone 4%. Material and methods: We carried out a pilot study on 30 Latin patients (skin type III and IV after Fitzpatrick’s classification). The product under study was applied on one side of the face and hydroquinone on the other, during 60 days. Results: The study product demonstrated effectiveness comparable to 4% hydroquinone in the 60 days of monitoring time. The hyperpigmentations are of a chronic type and so, considering the formula of the study product, it has the great advantage of permitting use for a prolonged period of time without the risk of undesirable side effects such as ochronosis. Tolerance for the product was excellent as well, both for daytime and night-time formulations, and neither irritation reactions nor allergic reactions were present during the period of use. Conclusions: The combined use of active substances is similar and comparable to hydroquinone in a 60 day period. The foundation can be laid for future studies to approach a new investigation with a larger number of patients, in which the use of hydroquinone can be established in comparison with this new treatment, so as to allow a statistically significant relationship to be established. Additionally, by studying a larger number of participants, it would allow this new product to be set up as an effective alternative treatment for melasma.en_US
dc.language.isoenen_US
dc.publisherMinisterul Sănătăţii al Republicii Moldova, Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”en_US
dc.relation.ispartofCurierul Medical
dc.subjectfacial melasmaen_US
dc.subjectantipigment skin agentsen_US
dc.subject.meshMelanosis--drug therapyen_US
dc.subject.meshFacial Dermatoses--drug therapyen_US
dc.subject.meshSkin Pigmentation--drug effectsen_US
dc.subject.meshHydroquinones--therapeutic useen_US
dc.titleComparative clinical study of depigmentation products on facial melasma in Latin womenen_US
dc.typeArticleen_US
Appears in Collections:Curierul Medical, 2016, Vol. 59, No 4

Files in This Item:
File Description SizeFormat 
Comparative_clinical_study_of_depigmentation_products_on_facial_melasma_in_Latin_women.pdf114.9 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback